Want to save up to 80% on your medications? Signup below to be notified if we open a Canadian Online Pharmacy.
Thanks for Visiting Canada Drugs Direct.
Currently we are preparing to serve our canadian visitors, we will update you when we are ready!
Please save your reference number: for further communication.
Sign up to get exclusive coupon discounts and be the first to be notified when we have this product available.
We guarantee the lowest price on all of our prescription products. If you find your medications cheaper at any other recognized licensed mail order pharmacy, we will not only match their price, we will beat it by 25% of the difference. It is our 125% price match guarantee!
Example: If you find a product on Canada Drugs Direct for $50.00 and find the same product for $40.00 at another mail order pharmacy, we will provide you with a $12.50 discount, bringing your total to $37.50.
To get the discount please make sure to mention the price match to the customer service team when they call to collect payment for your order. Or call toll free at 1-888-904-8467 to place the order through the phone.
Terms & Conditions of Program
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
XULTOPHY (insulin degludec and liraglutide) is a combination medication prescribed to treat high blood sugar (hyperglycemia) in patients with type 2 diabetes mellitus. It should be used in addition to diet and exercise to improve glycemic control.
The doctor will determine the starting dose of XULTOPHY; the possible starting doses are:
The maximum daily dose is 50 units of insulin degludec and 1.8 mg of liraglutide once daily.
XULTOPHY is injected under the skin once daily at the same time each day. Rotate injection sites to lower the risk of lipodystrophy and localized cutaneous amyloidosis.
XULTOPHY contains two active ingredients mixed in the same solution.
The first ingredient is insulin degludec, long-acting insulin that works for 24 hours in most people.
The second ingredient is liraglutide, a GLP-1 receptor agonist. Liraglutide works by causing the pancreas to release extra insulin.
Liraglutide slows down the movement of food through the gastrointestinal tract. Therefore, it may affect the absorption of certain medications like:
XULTOPHY contains insulin, and any insulin treatment carries a high risk of hypoglycemia. Ask your doctor or pharmacist how to recognize hypoglycemia. The following medications can mask the signs and symptoms of low blood sugar:
Some medications can raise or lower blood sugar in people with diabetes; examples include:
XULTOPHY insulin/GLP-1RA combination is contraindicated in people who have a personal or family history of Medullary Thyroid Cancer (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
XULTOPHY is not indicated for diabetic ketoacidosis or type 1 diabetes mellitus.
Monitor blood sugar closely while taking XULTOPHY and tell your doctor about any lifestyle changes that could affect your blood sugar.
Tell your doctor if you have a history of kidney disease, liver disease, cardiovascular disease, or gallbladder disease.
The most common adverse effects of Xultophy may include:
Buy XULTOPHY insulin/GLP-1 receptor agonist combination from Canada Drugs Direct.
Xultophy [package insert] Plainsboro, NJ: Novo Nordisk; 2019.